Abstract
Natalizumab, a humanized monoclonal antibody against α4 integrin, has been shown to significantly reduce the rate of clinical relapse, the development of T2 and gadolinium-enhancing magnetic resonance imaging (MRI) lesions, and the progression of disability in patients with relapsing forms of multiple sclerosis (MS).1,2 There have been more than 50 cases of progressive multifocal leukoencephalopathy (PML) in patients with MS receiving natalizumab, all developing after at least 1 year of therapy. Evidence suggests that the risk of developing PML is higher with prolonged periods of immunosupression.3